Daniel McGrath’s Post

✨🚀 I'm pleased to introduce Shoji Kuroyama as the newest member joining me on the #50lunches50leaders series 🚀✨.   After graduating Saitama University (BSc. - Applied Chem.), he started his pharmaceutical journey with Kirin Pharmaceuticals Co., Ltd. (merged with Kyowa Hakko in 2008). The initial 8 years were spent in field sales & then marketing before taking a leap of faith 🙏.   Self-funding his MBA, he booked his flight, packed his suitcase & enrolled 🏫 in business school at the The State University of New York 🇺🇸.   Like a lot of fresh 'US biz school grads' before him, Shoji landed his next role via the Boston Career Forum with The Janssen Pharmaceutical Companies of Johnson & Johnson securing his services.   He remained there for 15 years & was a critical player in building 🏗️ out their oncology commercial capabilities. Director & Senior Director roles were held down in sales & marketing, including a regional role based out of Singapore 🇸🇬 for 2 years. Seconded to Actelion (now Janssen Pulmonary Hypertension), he then worked as Head of Sales & Marketing for about 2 years before changing gears ⚙️ and taking a new challenge.   Joining Incyte as Executive Director, Head of Product & Commercial Strategy, a 4️⃣ year period followed where he oversaw the launch of 1 product & 1 line extension. Wearing multiple hats 🎩, including Sales & Marketing, CommEx, Market Access, Pricing, Business Development & New Product Planning 📊, it was a role that saw him accumulate enough experience to then challenge a #1 role.   As of June this year, Shoji has been President & Representative Director at Recordati & tasked with driving the Japan 🇯🇵 business to the next stage of it's evolution 📈 in the local market over the next 18 months 🗓️.             "Whilst delegation is super important, I'm also a strong advocate of the 'leading by example' approach.   Many years back when the global 🌏 chairman of Janssen was visiting Japan, he expressed this mantra of leading by example & it certainly left a strong impression 🤔 on me.   Another approach I take is this 'facilitation leadership style'. Throughout my people management career, I've been fortunate enough to be surrounded by experts with far deeper experience in their specialized areas. A key 🔑 part of my role is to help foster an environment where freedom to speak openly, communicate as clearly as possible & encourage open-mindedness is understood & embraced by all.   Finally, I like to tap into company-wide talent to determine the right solution to improve the business 🎯. Having a diverse employee-base with regards to age, ♀️gender ♂️, nationality, functional experience, work backgrounds, is a great weapon to utilize when seeking to understand a different view 👀 of things. This mix of mind-sets help provide a variety of thought that is impossible to achieve by oneself."     Thanks very much Shoji for joining the leadership series & wishing yourself & Recordati great success 🎆 moving forward! 👍👍

🚀🚀 The next professional to join me on my 50 Lunches 🍽 50 Leaders campaign is SUSUMU ADACHI 🚀🚀. In one of the more unique career pathways 🛣 for a Japanese MD, it was certainly an entertaining 💫 sit down listening to Susumu describe his career. Upon graduating Nara Medical University, a 1️⃣5️⃣ year period followed where he worked at multiple hospitals 🏥 before embarking on his pharma career. Eli Lilly and Company gave him his entry 🚪, where he remained for 13 years working at both their Japan 🇯🇵 and US 🇺🇸 offices. Initially rotating through drug safety, clinical development and medical, an opportunity to take on a global assignment arose which he took with both hands 👐. Pushing more into the commercial world 🌎, Susumu spent a year as an MR (North Carolina) and Sales Supervisor (Illinois) before a return to Japan and stepping into a Senior Director of Oncology BU role. The following 6 years he led roughly 200 people in this BU where they smashed 🔨 multiple sales records. AbbVie acquired his services next where he remained for 8 years as Medical Director, the final 2 of those spent in Singapore 🇸🇬 as JAPAC Immunology Head. Since August 2022, Susumu has been General Manager, Japan at BeiGene. His mission 👨🚀 is quite clear, build out the local office and bring their cutting-edge cancer treatments to Japan. "One constant focus I have when leading, whether that be in sales, R&D, medical or even back-office, is to always be receptive to feedback👂. Creating an environment where people feel comfortable in openly sharing their views is critical to overall success 🎆. Perhaps earlier in my career, I felt that I could always decide, which can be viewed as a strength but also a weakness. As I've grown as a leader, seeking out opinions has been a priority and this has often been the best way for the team, department and company as a whole, to improve." Thanks a lot SUSUMU ADACHI for sharing your insights and joining me on my Leadership Series. Wishing you and BeiGene great success for what looks to be an exciting year ahead! 👍👍 #leader #leadershipdevelopment #mindset #inspire #motivate #empower #effectivecommunication #pharmaceutical #healthcare #oncology #lunchandlearn #50lunches50leaders #greatsuccess

Kicking things ⚽ off in January, I'm pleased to introduce sho oshikawa as the first 50 Lunches 🍽 50 Leaders member for 2024❗ Highlighting 🔍 a different flavor to the previous leaders in this series, Sho experimented in several other industries (retail, industrial/manufacturing and IT) before landing in the healthcare sector. For 1️⃣5️⃣+ years, senior sales/marketing and supply chain roles were held down at RadioShack, Nippon Steel Corporation, Mars and Dell Technologies. A transition to the medical device industry at Stryker, saw a successful 8 year period where Sho and his team launched 🚀 many products into the Japan 🇯🇵market via his crucial role as Senior Director covering RA, QA and Public Affairs. Moving next to the pharmaceutical 💉 side, a 6 year stint followed at Biogen as VP of Pharmaceutical & Technology and Global Distribution Business (APAC). The most recent 3 years have seen him overseeing a period of integration 🤝 at the rare disease biopharma, Alexion Pharmaceuticals, Inc. (AstraZeneca) as Chief of Staff, Strategic Planning Office. "I like to describe my people management style as goal 🎯 oriented leadership. Irrespective of whether I'm overseeing 1 or 150 members, I like to apply the same principles. This initially focuses on determining what our vision 👓 and mission is, then making sure we are all aligned. Then we move onto setting up a clearly defined goal 🥅 and ensure we have the right strategy to execute on this.   I've found that if I hire the right people 💪 and put them in the right position, then half my job is done. Always support and encourage 😊 thereafter, but basically get out of their way! The best results 📈 are achieved when they have autonomy and ownership, so I allow them to have such freedom. Finally, I like to do as much as I can to make sure my members are progressing their career ↗ and taking on new challenges. This even includes me training up and standing aside when successors are ready to take on my role." Many thanks sho oshikawa for getting on board the 'great success' train 🚂 and sharing your insights. Best of luck for the year ahead! 👍👍 #leader #leadershipdevelopment #effectiveleadership #empoweringothers #mindset #inspire #motivate #healthcare #greatsuccess

"We were competing everywhere and winning nowhere" Tom Keith-Roach, president of AstraZeneca UK. On taking over the $250 million Korean business unit. How he turned this division around; 1. Exiting all markets where they didn't have a path to be a leader. “Strategy is the art of making decisions on where to compete, and where to say no" 2. Doubling down on people; "we had smart, driven people, but they were focusing all of their time and effort on maintaining the status quo. 3. Leveraging partnerships "we made our goal to be the #1 hospital products company, and we only inked partnerships which supported that." In my current role as a growth leader, I'm amplifying our core strengths: 1. Our people: we are a smaller team, but we're operating at the level of organisations 10x - 100x larger than us. this means being smarter with our time and activity 2. Powerful Platform: Top executives confirm our intelligence platform is unmatched, providing unique, decision-critical data. 3. Devoted Customers: bridging new executive connections with their transformative success stories. All of this starts with focus, and choosing where to amplify our strengths to succeed. We can do anything, but not everything.

Hi LinkedIn community, it’s Mitchell Denny here sharing some thoughts and reflections on 10 years of C2 PHARMA! 😁   I was an early starter with the company, with my first official day being all the way back in August 2014. Prior to that however, I still remember where I was (in Singapore on a business trip from the USA) when Andrew Badrot called in late 2013 to talk about a potential acquisition of a portfolio of #apis from Boehringer Ingelheim in Germany. Andrew and I had worked together and stayed in contact since 2005. After that first call, it didn’t seem to take long before the new company came along, and a new role for me was a reality! 💼   Returning home with my family to New Zealand late in 2014 and taking up responsibility for business development for the Asia-Pacific region was both challenging and exciting. Early on it became obvious that we could not seriously develop business in the APAC region without local partners and a lot of direct facetime with partners and customers alike. Of equal importance was having a team within our organization that was capable of supporting #asia and the other regions of the world where we were active. 🌏   In my role with C-squared Pharma, I have come to deeply value and appreciate my colleagues and our partners. Being in a small, dynamic business means that there are often seemingly oversized challenges and obstacles to overcome in order to succeed, and I must say that it is truly a privilege to have met and worked with such great partners and colleagues over the years. Being remote from our offices in Europe, I have especially appreciated regular contact with our partners in the APAC region. Longstanding partners such as Masung Life Sciences in Korea and Pyxchemi KK in Japan, who have been with us from the start, bring invaluable local experience and knowledge to our business. 🤝   I have also appreciated the opportunity to become a part of the #pharma industry. The world of APIs is continuously fascinating and ever-changing. There is always something new to learn and always new prospects and projects to explore. As we move into the next chapter as the global leader in ophthalmic APIs there is a lot more to learn and do! 🤓   C-squared Pharma has achieved a great deal in its first 10 years, and I’m sure there is a lot more to come!! #Cheers2Tenyears 🍻  

Full disclosure, the first 15 mins of our lunch 🍴 were spent bemoaning 😭 the demise of our once proud football club, Manchester United❗ 🌟🚀 On that note, I'm pleased to introduce Philip Miller as the next professional on the #50lunches50leaders series 🌟🚀 Once we unpacked 🛅 those collective frustrations, it dawned on me that the start of the Red Devils slide, strangely coincided with Phil's own career going into overdrive & the fortunes of both parties have been going in different directions ↔ ever since!    Coming from a family of scientists ⚕, it was no surprise Phil found himself in a laboratory at GSK to start his career. The world 🌍 of molecular pharmacology/DMPK kept him engaged for 5 years (also gaining his Ph.D from the University of Leeds), but a desire to further challenge himself saw him enter the management consulting space. Jumping in the deep end, he entered Deallus as the 8th employee worldwide. Starting as a Research Consultant/Analyst, he exited 7 years later as Head of EMEA & LATAM. This conversion period of academia/science to commercial/business saw him experience dozens of projects with a huge range of 💊 pharma/biotech clients.   Astellas Pharma next secured his services & he remained in their EU business for the next 4 years. First in the UK 🇬🇧 as Senior Director, Corporate Strategy & Planning for EMEA & then Head of Sales & Marketing in Austria 🇦🇹. Clearly impressing the folks at HQ, the next step was bringing him & his family to Japan 🇯🇵 where he continued his work in Corporate & Portfolio Strategy, as Executive Director & then VP for a further 4 years. Wishing to remain in Japan 🌸, an expansion role opened at Novartis, where he has remained since mid 2023. As Head of Strategy & Growth, he oversees NPP, Launch Excellence, Business Development, Strategy & Governance & in this role, he encourages his team to focus on outcome over process. "If you're solving a complex problem 🤔, it's important to keep focussed on the outcome versus sticking with the original plan & unintentionally compromising on quality. It's about working through ambiguity, learning & adapting the process as you go, while keeping leaders close enough to the team & the subject matter to have a view 🔭 on whether initiatives are moving at the right pace & in the right direction.   It is in this environment where I've found teams produce their best work & can operate with confidence that the output is genuinely what matters rather than sticking to arbitrary deadlines.   The Japanese business environment can typically be quite process-minded & hierarchical. However, it's important to have the courage to say we don't know the answer yet & we don't know every step 👣 we will take. In my experience, this openness is usually appreciated, encourages constructive engagement & creates the best conditions for ⚡ success!" Thanks a lot Philip for joining me for a feed & wishing you (& Man U) great success for the year (season ⚽) ahead! 👍👍

In my first few months as the General Manager of Takeda Pharma Austria, I've embarked on a journey guided by three foundational pillars: people, culture, and the business. Each pillar holds its own significance, but it's the people—the heartbeat of our organization—that I find most captivating and impactful.   Exploring the intricate tapestry of individuals within our team has been nothing short of enlightening. From diverse backgrounds to unique skill sets, every member brings a story worth hearing and talents waiting to be unleashed. It's within these personal narratives that the true essence of our organization resides, fostering collaboration, prioritization, and performance.   As we navigate our teams journey towards continued high-performance, I am continually inspired by the wealth of potential and passion I encounter daily. The journey is dynamic, with challenges and triumphs alike, but it's the unwavering dedication and camaraderie among our team that fuels our progress. Together, we're not just shaping a company—we're fostering a culture of excellence and growth.   And amidst the hustle and bustle of leadership, I find solace and joy in the simple act of getting to know and understand each member of our team. It's a privilege—one that I don't take lightly. Their aspirations, struggles, and dreams fuel my determination to lead with empathy, integrity, and purpose.   So here's to the countless stories yet to be told, the milestones waiting to be achieved, and the bonds waiting to be forged. Here's to the relentless pursuit of excellence and the unwavering belief in the power of our people. Together, we're not just charting a course for success—we're redefining what it means to thrive as a team.   #LeadershipJourney #HighPerformanceTeams #TakedaAustria

In this week's episode, Samuel Hollis (Novartis UK) shares his journey in the pharmaceutical industry, a career spanning close to 2 decades working in the UK, Switzerland and US in roles from sales rep, medical affairs to global marketing and business unit head to now gearing up to start as a country president in Central Europe, not to mention his 🦞 theory! We discussed: 🏥 The role of medical affairs and why people should join the industry 🌟 Why 21st century leadership is about authenticity, vulnerability and entrepreneurship 💊 The process of a medicine coming to market 🇬🇧🇺🇸 Learnings from working in the UK vs US 🔬 The importance of innovation and staying competitive 🛠️ Building real solutions to real problems 🔄 Transitioning from AstraZeneca to Novartis UK 🌱 Growth and leadership mindset 🦞 'Be More Lobster' 🤝 Why collaboration and partnerships between healthcare systems and industry are built on trust 💼 The reputation of pharma and myth busting 🔨 How to build trust and 'Purpose-led collaborations' 📉 Learning from failures, commercial R&D and building the right working cultures 🌍 New role as country president at Novartis 🎓 Tips for building a career in the pharma industry Link in the comments!

⭐⭐ The next top pharmaceutical professional we are rolling out in the 50 Lunches 🍽 50 Leaders series is Philippe Auvaro. ⭐⭐ A long standing and well-known member in the Japan 🇯🇵 healthcare industry, Philippe was kind enough to share his time and insights from a career spanning 3️⃣ decades. Of which, 25➕ years have been spent in the APAC region (with almost 20 of those in Japan). The first time Philippe landed 🛩 in Narita, it was in 1986 as a business school 🏫 student. Beginning his career with Hoechst Marion Roussel and then Aventis, Philippe quickly progressed in the organization and was appointed General Manager Taiwan where he experienced his first merger and acquisition from Hoechst Marion Roussel to Aventis (now Sanofi). A further regional assignment in Korea 🇰🇷 sitting across a COO position at Handok Pharmaceuticals (back then a joint 🤝 venture with Aventis) and the direction of the local affiliate followed before a career move and a return to Japan with GSK. For more than a decade, he held down VP and Corporate Officer roles there before accepting a new ✨ challenge as President for Aspen Pharma Group, a long-term global partner of GSK seeking help to create their business in Japan. CMIC Group was the next opportunity he grabbed where he remained for over 5 years as Executive Director and President of OrphanPacific Inc., the pharma business arm 💪 of CMIC Holdings. Finally, the last 2️⃣ years have seen Philippe work as Executive Director at the pioneer of real world data in Japan, Medical Data Vision (MDV). "Being thrust into a key leadership post as GM of Taiwan 🇹🇼 at 33, it was really a case of sink or swim 🏊♂️! When I reflect on my years in leadership roles, I am sure I could be described in various ways. Everything from stubborn, demanding, empowering to conciliatory, encouraging 👏 and hopefully, motivating, could all be words used by my team members and peers! One thing I have learnt over the journey 🚶♂️ is that things change with time, so the ability to adjust as a leader is a critical skill. Now I believe my style is very much focused around people-centered leadership 😊 and always being mindful of how the other side is feeling/thinking, though I am not too sure to correctly “read the wind” all the time." Appreciate the deep reflections 🤔 and refreshing thoughts on your people management experiences Philippe! Thanks for contributing to this leadership series and wishing you 'great success' for the year ahead. 🚀👍👍🚀 #leader #leadershipdevelopment #mindset #inspire #motivate #empower #effectivecommunication #pharmaceutical #healthcare #lunchandlearn #50lunches50leaders #greatsuccess

The #50lunches50leaders 🍽 series is dropping into the CRO world 🌏 this week with 2️⃣ big players sharing their stories & leadership journeys.   🚀I'm pleased to introduce the first such professional is Stephane Gouteux🚀   In a childhood spent traversing the globe (living in Brazil 🇧🇷, Chile 🇨🇱, Italy 🇮🇹), it is no surprise this native-Frenchman's 🇫🇷 work career has followed a similar pathway.   At the completion of his studies 📚, including a PhD (neurosciences) from Aix-Marseille University, Stephane entered the healthcare world via ICON plc.   A 4.5 year stint followed in clinical research before a move to Idenix Pharma (acquired by Merck in 2014) for a following 3 years in project management.     A move to Switzerland 🇨🇭 with Merck Healthcare was the next stop in Stephane's career & he remained here for 6.5 years. Initially as an Associate Director in Geneva before an international ✈ transfer brought him to Japan 🇯🇵, first as Department Head - CTM, then Head of Global Clinical Operations (Japan & North-East Asia).   IQVIA were next to identify his value in this region by offering a Senior Director - Head of Oncology Project Leadership (APAC) role which saw him pack the family's suitcases 🛄 and move to Singapore 🇸🇬. After 3.5 years in that position, a transfer was yet again made to Dubai 🇦🇪 where he stayed for a further 18 months. That position of Head of R&D Solutions saw him oversee a huge region including the Middle East & Africa.   A return to Japan arrived in 2019 when Syneos Health secured Stephane's services as VP & General Manager - Japan Clinical Solutions Business. Despite the COVID-years, he has overseen a huge period of expansion 📊 for the business including an almost 80% increase 📈 in clinical headcount.   "As a Leader, I firmly believe that the greatest asset ✅ for a company is always the talent within it.   This employee-centric focus 🔍 has been a constant part of my career, starting with the very first people management role I had all the way through to the present day.   I try to not overcomplicate things and simply put, a happy 😃, engaged, valued employee is a productive one. This doesn't mean we have to be best friends or be super nice every minute ⏳ of every day, but I always communicate with transparency, empathy, respect 🙏 & with fairness in mind.   Leading is also understanding and reacting to the constant evolution of our environment & to adjust our strategy appropriately. The recent COVID-19 pandemic ⛑ gave us a great opportunity to adjust the employee ecosystem for more flexibility & better work/life balance. Developing this vision into tangible outcomes was key 🔑 to attract & retain talent. For me, Leadership is, for sure, the ability of taking bold steps 👣 that will ensure the success of your business!"   Many thanks Stephane for joining me on this leadership series & wishing you 'great success' for the year ahead! 👍👍   #50lunches50leaders #lunchandlearn #leaderscreateleaders